

**Fiscal Year 2011 (FY11) Defense Medical Research and Development Program  
Reference Table of Award Mechanisms and Submission Requirements**

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Military Infectious Diseases Basic Research Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li>• <a href="#">Program Announcement</a></li> <li>• <a href="#">Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-11-DMRDP-MIDBRA</a></p>	<ul style="list-style-type: none"> <li>• Independent investigators at any academic level (or equivalent) are eligible to submit applications.</li> <li>• This Program Announcement / Funding Opportunity is open to extramural investigators or extramural investigators with one or more intramural collaborator(s).</li> </ul>	<ul style="list-style-type: none"> <li>• Supports research aimed at identifying, characterizing, and/or clarifying basic biological mechanisms related to microbes responsible for combat-related wound infections.</li> <li>• Will not support applied research or clinical trials</li> <li>• Preliminary data is encouraged but not required</li> <li>• Applications must address one or more of the following focus areas:               <ol style="list-style-type: none"> <li>1. Discovery and characterization of the factors that regulate the dynamic states between normal tissue, injury, healing, and infection, to include biofilm formation processes.</li> <li>2. Identification and characterization of microbial virulence factors (including drug resistance mechanisms) and other potential therapeutic targets of metabolic or signaling pathways associated with wound infection and/or biofilm formation, maintenance, and propagation processes.</li> <li>3. Identification and characterization of novel chemotypes (chemical classes/materials) and/or biologics (e.g., drugs, immunomodulators, etc.) with potential as therapeutics or prophylactics for wound infection and/or biofilm processes.</li> </ol> </li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of \$1 Million (M) for total (direct and indirect) costs</li> <li>• Period of performance up to 2 years</li> <li>• Anticipate approximately 7 awards</li> </ul>	<p><b>Pre-application:</b> September 13, 2011 5:00 p.m. Eastern Time</p> <p><b>Invitation to Submit an Application:</b> October 2011</p> <p><b>Application:</b> December 7, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
<p><b>Military Infectious Diseases Applied Research Award</b></p> <p>Go to:</p> <ul style="list-style-type: none"> <li><a href="#">Program Announcement</a></li> <li><a href="#">Application Instructions</a></li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b></p> <p><a href="#">W81XWH-11-DMRDP-MID-ARA</a></p>	<ul style="list-style-type: none"> <li>Independent investigators at any academic level (or equivalent) are eligible to submit applications.</li> <li>This Program Announcement / Funding Opportunity is open to extramural investigators or extramural investigators with one or more intramural collaborator(s).</li> </ul>	<ul style="list-style-type: none"> <li>Seeks applications focused on reduction of morbidity and mortality of infections of trauma-induced wounds in Wounded Warriors (combat-related wound infections)</li> <li>Applied research may evaluate, mature, and/or downselect potential product candidates (drugs, biologic/vaccine constructs, or devices/systems) in vitro and/or in vivo, and may consist of preclinical safety and/or toxicity studies sufficient to support Investigational New Drug/Investigational Device Exemption (IND/IDE) applications.</li> <li>Preliminary data are required</li> <li>Awards may support studies with human subjects but may not be used to support clinical trials or basic research</li> <li>All applications must address at least one of the following focus areas related to combat-related wound infections: <ul style="list-style-type: none"> <li>Development of new methods for rapid multi-pathogen/multi-phenotype detection of multidrug-resistant organisms (MDROs) and/or nosocomial pathogens, [particularly <i>Acinetobacter baumannii</i>, <i>Pseudomonas aeruginosa</i>, extended-spectrum beta-lactamase producing <i>Enterobacteriaceae</i> (including <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i>), and methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), and/or invasive fungal (mold) pathogens], and/or rapid multi-pathogen/multi-phenotype characterization of antimicrobial</li> </ul> </li> </ul>	<ul style="list-style-type: none"> <li>Maximum funding of \$2 Million (M) for total (direct and indirect) costs</li> <li>The maximum period of performance is 3 years</li> <li>Anticipate approximately 5 awards</li> </ul>	<p><b>Pre-application:</b> September 13, 2011 5:00 p.m. Eastern Time</p> <p><b>Invitation to Submit an Application:</b> October 2011</p> <p><b>Application:</b> December 7, 2011 11:59 p.m. Eastern Time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadlines
		<p>resistance patterns.</p> <ul style="list-style-type: none"> <li>○ Development of assays for host immune response biomarkers for diagnosis or prognosis of infection to inform clinical wound management decisions.</li> <li>○ Development and preclinical testing of novel chemotypes (chemical classes/materials) and/or biologics as potential therapeutics or prophylactics for wound infection and/or biofilm formation, maintenance, or propagation. Innovative treatment approaches (e.g., chelators, antibody, phage, antimicrobial peptides, quorum-sensing inhibitors, and host immun augmentation, etc.) are encouraged.</li> </ul>		